BIOLINERX Ltd/S (BLRX) Receives “Buy” Rating from Maxim Group

BIOLINERX Ltd/S (NASDAQ:BLRX)‘s stock had its “buy” rating restated by investment analysts at Maxim Group in a report released on Thursday. They currently have a $2.00 target price on the biotechnology company’s stock. Maxim Group’s price target suggests a potential upside of 177.78% from the company’s previous close.

The analysts wrote, “BioLineRx reported 3Q18 with a net loss of ($6.2M) and ended the quarter with $35M in cash on the balance sheet. We estimate a runway to late 2019.””

BLRX has been the topic of a number of other reports. HC Wainwright set a $4.00 target price on shares of BIOLINERX Ltd/S and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Zacks Investment Research lowered shares of BIOLINERX Ltd/S from a “buy” rating to a “hold” rating in a research report on Tuesday, July 24th. ValuEngine raised shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a research report on Tuesday, October 16th. Finally, MED started coverage on shares of BIOLINERX Ltd/S in a research report on Wednesday, August 1st. They set a “market perform” rating on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. BIOLINERX Ltd/S currently has an average rating of “Buy” and an average price target of $2.50.

Shares of NASDAQ:BLRX traded down $0.02 during trading on Thursday, reaching $0.72. 21,643 shares of the company were exchanged, compared to its average volume of 1,904,600. The firm has a market cap of $75.20 million, a PE ratio of -2.67 and a beta of 0.87. BIOLINERX Ltd/S has a 12-month low of $0.67 and a 12-month high of $1.84.

BIOLINERX Ltd/S (NASDAQ:BLRX) last issued its earnings results on Monday, August 13th. The biotechnology company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. On average, sell-side analysts expect that BIOLINERX Ltd/S will post -0.22 EPS for the current fiscal year.


BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Read More: Diversification

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with's FREE daily email newsletter.

Leave a Reply